HAIRLOSSHELP: Tell us about your company.

STEVEN PORTER: Osmotics was started by my wife Francine and myself in 1993. Our goal has been to make Osmotics the world's premiere skin care company - to achieve and introduce a new level of real results in cosmeceutical and dermaceutical skin care treatments. We have done this by combining patented delivery technologies with scientifically proven ingredients, Osmotics is on the cutting edge of cosmeceutical and therapeutic skin care. This innovative, unprecedented strategy is the cornerstone of Osmotics philosophy.

We also work with leading university medical centers and renowned scientists around the world to utilize the latest breakthroughs and most advanced thinking in developing truly effective products. These unique formulations feature proven technologies and patented compounds from the biopharmaceutical and biotechnological fields. All product claims have been validated through independent clinical testing, a first in this industry.

HAIRLOSSHELP: How much are your annual gross revenues?

STEVEN PORTER: Osmotics is a privately held and does not publicly disclose financial details.

HAIRLOSSHELP: Where or how are your existing products currently sold?

STEVEN PORTER: Our products are sold at Sak's Fifth Avenue stores, Bergdorf Goodman's, Nordstrom's, Sephora's, Jacobsen's, through our website, and other leading stores.

HAIRLOSSHELP: What made you enter the hair loss market?

STEVEN PORTER: We only enter a market when we believe that we can bring an innovative and significant improvement based on scientifically credible evidence. We are not interested in me-too products. When we learned about Professor Lindenbaum's work we were very interested. Although our focus has been on skin care, when we examined the data from the double-blind study in Israel, we knew that this technology was very significant and that millions of people would benefit from its commercialization.

HAIRLOSSHELP: I believe that your company already licenses ProCyte's copper peptide for use in your skin care line. American Crew recently licensed the Tricomin copper peptide, why did you decide to license Piliel when you could have licensed Tricomin like American Crew?

STEVEN PORTER: Osmotics was the first company to create a product based on copper peptides. We did in fact license a copper peptide from ProCyte but that relationship has ended. Our current copper products are based on formulations that Osmotics has developed. We licensed the Piliel technology based on our review of the scientific data.

HAIRLOSSHELP: How did you meet Prof Lindenbaum, were you looking for a hair loss product and found her or did she find you?

STEVEN PORTER: Professor Lindenbaum's technology was listed as a technology that was available for licensing on the Technion Institute's technology transfer site. As we are always looking for innovative and significant technologies, we decided to investigate this opportunity. We contacted the Technion and they put us in touch with Professor Lindenbaum.

HAIRLOSSHELP: Lets talk about Piliel. FNS has a past history as Piliel so we need to know more about Piliel so we can see your product in the correct perspective. Why did Life Medical Sciences terminate its clinical trials of Piliel? The initial small-scale studies by Prof Lindenbaum seemed so promising?

STEVEN PORTER: In developing a new product, it is critically important to work closely with the inventor. It is our understanding that Professor Lindenbaum was not consulted regarding Life Medical Sciences's formulation of the product. As a result, the original formulation that was so promising in the Israeli study did not perform well at all in the European study. The formulation had been changed to include a bulking agent that reversed the flow of moisture and drew moisture up from the dermis into the epidermis. This adversely affected the ability of the nutrients in the formula to reach the hair follicles. We are pleased to have met with Professor Lindenbaum and she is an active participant in the formulation and development of FNS.

HAIRLOSSHELP: Do you have the results from the Piliel trial since they were never made public?

STEVEN PORTER: Yes, we have the results and Professor Lindenbaum has submitted them for publication in a peer-reviewed journal.

HAIRLOSSHELP: How does FNS differ from Piliel?

STEVEN PORTER: FNS is based on the original formula that was tested in the Israeli double-blind study. The formulation has been improved to increase the targeting of hair follicles.

HAIRLOSSHELP: Is it the exact same formulation developed by Prof Lindenbaum?

STEVEN PORTER: The ingredients are the same, the delivery vehicle has been changed to create a commercial product that is user friendly. In the Israeli study, the formula was delivered in syringes for use by the study participants.

HAIRLOSSHELP: What clinical trials has Osmotics conduced on FNS?

STEVEN PORTER: Osmotics is planning additional studies and will keep you advised once the results are publicly available. Based on our review of the Israeli data, we believe that we had sufficient information to launch a product based on the original formula. That data will be publicly available following publication in the medical journal.

HAIRLOSSHELP: The pictures that are on your web site now, are they from Prof Lindenbaum's initial trial or the Piliel European trials?

STEVEN PORTER: Those photos are from the Israeli double-blind study.

HAIRLOSSHELP: Who do you think would respond best to FNS from what you have seen from the clinical trials?

STEVEN PORTER: FNS is a product that we believe will help anyone who still has hair follicles. The trial data has been submitted for publication and will be disclosed at that time.

HAIRLOSSHELP: What exactly is FNS and what are its ingredients?

STEVEN PORTER: FNS is an enriched cell culture medium that is specifically formulated to provide the nutrients necessary for a healthy hair follicle. It also contains a non-steroidal anabolic hormone and a specially formulated vehicle.

HAIRLOSSHELP: How is it used and how often?

STEVEN PORTER: Once a night by applying it to those areas of the scalp where there is thinning hair.

HAIRLOSSHELP: Please explain how it works?

STEVEN PORTER: It works by supplying the nutrients that are necessary for the proper and healthy functioning of the hair follicle.

HAIRLOSSHELP: How is it packaged?

STEVEN PORTER: That is still to be determined and we are working on the packaging right now.

HAIRLOSSHELP: How much will it cost and how long will it last?

STEVEN PORTER: It will retail for around 60 dollars and will last 2 months.

HAIRLOSSHELP: I am under the impression that the FNS product comes with a spray type applicator. Would it not be more efficient to use a dropper, for those targeting specific thinning areas?

STEVEN PORTER: The product is formulated as a gel. FNS will not be a spray.

HAIRLOSSHELP: How does in interact with products like Rogaine Propecia and Tricomin?

STEVEN PORTER: We have not conducted clinical studies to determine how FNS works with other products. We expect to learn a lot from the experience of persons who decide to use FNS in conjunction with other hair treatments.

HAIRLOSSHELP: How long can people use if before expecting to see results?

STEVEN PORTER: Four to Six weeks. Before they have used up their first tube.

HAIRLOSSHELP: Does it require constant usage and if not why?

STEVEN PORTER: It should be used regularly for 9 months. Based on results, the user may elect to use the product less frequently as a maintenance therapy. The product's benefits do not require lifetime usage at the same rate.

HAIRLOSSHELP: Do you recommend that it be used in combination with other products, or as a stand-alone product?

STEVEN PORTER: We believe that the product offers significant benefits as a stand-alone product. We look forward to learning from our customers whether additional benefits may be obtained by combining its use with other products.

HAIRLOSSHELP: Are there any side effects noted?

STEVEN PORTER: No.

Continued on next page